Abstract
In October 2009, pazopanib (Votrient; GlaxoSmithKline)--a multikinase inhibitor with targets that include vascular endothelial growth factor receptors--was approved by the US FDA for the treatment of advanced renal cell carcinoma.
MeSH terms
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use
-
Carcinoma, Renal Cell / drug therapy*
-
Carcinoma, Renal Cell / physiopathology
-
Clinical Trials as Topic
-
Drug Delivery Systems
-
Humans
-
Indazoles
-
Kidney Neoplasms / drug therapy*
-
Kidney Neoplasms / physiopathology
-
Protein Kinase Inhibitors / adverse effects
-
Protein Kinase Inhibitors / pharmacology
-
Protein Kinase Inhibitors / therapeutic use*
-
Pyrimidines / adverse effects
-
Pyrimidines / pharmacology
-
Pyrimidines / therapeutic use*
-
Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors
-
Sulfonamides / adverse effects
-
Sulfonamides / pharmacology
-
Sulfonamides / therapeutic use*
Substances
-
Antineoplastic Agents
-
Indazoles
-
Protein Kinase Inhibitors
-
Pyrimidines
-
Sulfonamides
-
pazopanib
-
Receptors, Vascular Endothelial Growth Factor